Lataa...
Immune checkpoint inhibitors in challenging populations
Immune checkpoint inhibitors, including those targeting the PD-1/PD-L1 and CTLA-4 pathways, are revolutionizing cancer therapeutics. Both activity and toxicities largely stem from unleashing tumor- or host-specific cytotoxic T cells. Many patients seen in routine clinical practice did not qualify fo...
Tallennettuna:
| Julkaisussa: | Cancer |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5445005/ https://ncbi.nlm.nih.gov/pubmed/28241095 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30642 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|